1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

Strange Bedfellows: Generics Firms Join Big Pharma In Opposing Price Negotiation Legislation

 
• By Cathy Kelly

Concerns that Medicare drug price negotiation provisions in the Build Back Better legislation would upend the generic and biosimilar industries might resonate with legislators more than complaints from branded drug companies.

Innovator And Generics/Biosimilars Sectors Often Not On Same Side • Source: Alamy

In a twist that could help big pharma’s cause, marketers of generic drugs and biosimilars have joined the fight against provisions in the Build Back Better bill that would empower the Health and Human Services Department to negotiate the prices of certain high-cost, single source drugs that have been on the market long enough for their initial period of exclusivity to expire.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

More from Market Access

Leqembi Launch Set For Germany & Austria After Winning EU Approval At Last

 
• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.

African Medicines Agency Set To Launch With New Leader In April

 
• By Anabel Costa-Ferreira

The African Medicines Agency is to appoint a director general and become operational at the end of this month.

EU Regulators Push For Better Support For Sponsors On Using Animal Study Alternatives

 
• By Eliza Slawther

The European Medicines Agency’s innovation network has recommended how the EU’s regulatory framework could be updated to support drug developers in using new approach methodologies, which are drug testing methods that reduce or replace animal studies.